Jyoti D. Patel

Research interests

Publications

• HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

  Journal of Clinical Oncology · 2023 · 10.1200/jco.23.01476

• Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

  Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.22.00912

• Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

  Cancer Discovery · 2021 · 10.1158/2159-8290.cd-20-1598

• Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2004407

• Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2005653

• Efficacy of Selpercatinib in RET -Altered Thyroid Cancers

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2005651

• Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30856-3

• Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2018.78.5204

• Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study

  Lung Cancer · 2018 · 10.1016/j.lungcan.2018.12.017

• Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2017.76.2229

• Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30691-5

• Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2016.71.9476

• NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016

  Journal of the National Comprehensive Cancer Network · 2016 · https://doi.org/10.6004/jnccn.2016.0031

• Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer

  Cancer Discovery · 2016 · 10.1158/2159-8290.cd-16-0686

• Non–Small Cell Lung Cancer, Version 6.2015

  Journal of the National Comprehensive Cancer Network · 2015 · 10.6004/jnccn.2015.0071

• Non–Small Cell Lung Cancer, Version 1.2015

  Journal of the National Comprehensive Cancer Network · 2014 · 10.6004/jnccn.2014.0176

• Non–Small Cell Lung Cancer, Version 2.2013

  Journal of the National Comprehensive Cancer Network · 2013 · 10.6004/jnccn.2013.0084

• Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2013.53.7076

• PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.47.9626

• Non–Small Cell Lung Cancer

  Journal of the National Comprehensive Cancer Network · 2012 · 10.6004/jnccn.2012.0130

• Non–Small Cell Lung Cancer

  Journal of the National Comprehensive Cancer Network · 2010 · 10.6004/jnccn.2010.0056

• Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.20.8181

• Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.13.0062

• Lung Cancer in US Women

  JAMA · 2004 · 10.1001/jama.291.14.1763

• Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2004 · 10.1200/jco.2004.08.158

Current projects

No projects listed.